To evaluate the therapeutic potential of NVG-2089, a recombinant IgG1 Fc-domain protein, in an animal model of inflammatory demyelinating neuropathy.
Key Findings:
Both NVG-2089 and IVIg stabilized motor and sensory performance.
Both treatments preserved compound muscle action potential (CMAP) amplitudes and attenuated demyelination-associated prolongation of distal latency and CMAP duration.
Morphometric analyses showed preservation of myelinated fiber density and normalization of g-ratio distributions in both treatment groups.
Immunophenotyping indicated an expansion of functionally activated CD25+CD39+ Tregs and increased FcγRIIB expression on immune cells.
Interpretation:
NVG-2089 demonstrated robust neuroprotective efficacy comparable to IVIg while requiring a substantially lower protein dose.
Limitations:
Conclusion:
These findings support NVG-2089 as a promising, dose-efficient alternative to IVIg for the treatment of inflammatory demyelinating neuropathies, including GBS and CIDP.
